Dopamine, Locus of Control, and the Exploration-Exploitation Tradeoff
Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenc...
Saved in:
Published in | Neuropsychopharmacology (New York, N.Y.) Vol. 40; no. 2; pp. 454 - 462 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Nature Publishing Group
01.01.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0893-133X 1740-634X 1740-634X |
DOI | 10.1038/npp.2014.193 |
Cover
Abstract | Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone. |
---|---|
AbstractList | Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone. Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone.Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone. |
Author | Frank, Michael J Mitchell, Jennifer M Kayser, Andrew S Weinstein, Dawn |
Author_xml | – sequence: 1 givenname: Andrew S surname: Kayser fullname: Kayser, Andrew S – sequence: 2 givenname: Jennifer M surname: Mitchell fullname: Mitchell, Jennifer M – sequence: 3 givenname: Dawn surname: Weinstein fullname: Weinstein, Dawn – sequence: 4 givenname: Michael J surname: Frank fullname: Frank, Michael J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25074639$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1P3DAQxS1EVRbojXMVqRcOm60n_sylElqWFmmlXkDiZjmOXYKydrATRP_7emGpCuLQ03jk3zy9mXeI9n3wFqETwAvARH71w7CoMNAF1GQPzUBQXHJCb_bRDMualEDIzQE6TOkOY2CCy4_ooGJYUE7qGVqdh0FvOm_nxTqYKRXBFcvgxxj6eaF9W4y3tlg9Dn2IeuyCL5_e3fjUFFdRtzY4d4w-ON0n-2lXj9D1xepq-aNc__x-uTxbl4YKOZbEasMqkMY5YI22TcUbgR2I1hoQzDUgWwaNqXmt20pz3GKBeWM4YUAYbcgR-vasO0zNxrbGZqO6V0PsNjr-VkF36vWP727Vr_CgKKWk5jgLnO4EYrifbBrVpkvG9r32NkxJAee0wpII-h8oEYxVkm_RL2_QuzBFny-xpRgmQoLI1Od_zf91_RJGBqpnwMSQUrROmd2h8y5drwCrbeIqJ662iauceB6avxl60X0X_wMonqyz |
CODEN | NEROEW |
CitedBy_id | crossref_primary_10_3389_fnins_2016_00106 crossref_primary_10_3389_fnins_2019_00065 crossref_primary_10_1111_gbb_12228 crossref_primary_10_1371_journal_pone_0176034 crossref_primary_10_1038_s41398_021_01512_6 crossref_primary_10_1038_s41386_021_01100_8 crossref_primary_10_17759_jmfp_2020090208 crossref_primary_10_1017_S1092852924000130 crossref_primary_10_1162_jocn_a_01641 crossref_primary_10_1007_s00213_020_05599_5 crossref_primary_10_1016_j_neunet_2020_03_005 crossref_primary_10_7554_eLife_59907 crossref_primary_10_1523_JNEUROSCI_1607_20_2021 crossref_primary_10_1016_j_psyneuen_2017_09_010 crossref_primary_10_3389_fnint_2018_00006 crossref_primary_10_1016_j_tics_2015_08_013 crossref_primary_10_7554_eLife_51260 crossref_primary_10_1016_j_neubiorev_2020_04_006 crossref_primary_10_1016_j_neuron_2019_07_021 crossref_primary_10_1371_journal_pcbi_1006989 crossref_primary_10_1007_s00213_019_05299_9 crossref_primary_10_1111_psyp_14571 crossref_primary_10_1002_wcs_1420 crossref_primary_10_1016_j_cobeha_2021_04_003 crossref_primary_10_1016_j_neuroscience_2021_05_010 crossref_primary_10_1080_17405629_2020_1816166 crossref_primary_10_1038_s41380_021_01363_z crossref_primary_10_1038_s41386_022_01517_9 crossref_primary_10_1016_j_brainres_2019_05_039 crossref_primary_10_1111_ejn_16426 crossref_primary_10_1038_ncomms10785 crossref_primary_10_1162_jocn_a_00896 crossref_primary_10_1523_ENEURO_0461_19_2020 crossref_primary_10_1007_s00213_018_4971_z crossref_primary_10_1016_j_nicl_2016_12_022 crossref_primary_10_1111_psyp_14381 crossref_primary_10_1016_j_neuroimage_2018_10_075 crossref_primary_10_1007_s40429_019_00240_8 crossref_primary_10_1016_j_jbi_2021_103913 crossref_primary_10_1016_j_neuron_2015_12_029 crossref_primary_10_1038_npp_2017_108 crossref_primary_10_1016_j_tics_2015_11_007 crossref_primary_10_3758_s13415_021_00917_6 crossref_primary_10_1016_j_neuron_2024_04_008 crossref_primary_10_1016_j_ijpsycho_2019_09_016 crossref_primary_10_1016_j_pneurobio_2022_102252 crossref_primary_10_7554_eLife_74149 crossref_primary_10_1371_journal_pone_0282727 crossref_primary_10_1038_npp_2015_208 |
Cites_doi | 10.1038/sj.npp.1301227 10.1016/j.neuron.2011.12.025 10.1016/j.neunet.2007.04.026 10.1016/j.biopsych.2011.03.028 10.1016/j.paid.2003.11.001 10.1523/JNEUROSCI.1180-12.2012 10.1073/pnas.95.17.9991 10.1016/j.bandc.2006.04.004 10.1038/nature04766 10.1038/nn.2723 10.1111/j.1460-9568.2009.06647.x 10.1371/journal.pone.0087109 10.1097/01.alc.0000191755.63639.4a 10.1097/00001756-199711100-00032 10.1037/a0037015 10.1007/s00213-012-2653-9 10.1093/cercor/bhr332 10.1016/j.biopsych.2010.10.015 10.1523/JNEUROSCI.3116-08.2008 10.1038/npp.2010.96 10.1002/syn.10034 10.1037/h0092976 10.1086/425589 10.1038/nn.2342 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1 10.1111/j.1469-8749.2008.02026.x 10.1038/nrn1343 |
ContentType | Journal Article |
Copyright | Copyright Nature Publishing Group Jan 2015 Copyright © 2015 American College of Neuropsychopharmacology 2015 American College of Neuropsychopharmacology |
Copyright_xml | – notice: Copyright Nature Publishing Group Jan 2015 – notice: Copyright © 2015 American College of Neuropsychopharmacology 2015 American College of Neuropsychopharmacology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
DOI | 10.1038/npp.2014.193 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Psychology Database (ProQuest) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Psychology MEDLINE - Academic MEDLINE Neurosciences Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Dopamine and exploration |
EISSN | 1740-634X |
EndPage | 462 |
ExternalDocumentID | PMC4443960 3522567981 25074639 10_1038_npp_2014_193 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US San Francisco California |
GeographicLocations_xml | – name: San Francisco California – name: United States--US |
GroupedDBID | --- -DZ -Q- 0R~ 29N 2WC 36B 39C 4.4 406 5RE 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AANZL AASML AAYXX AAYZH ABAKF ABBRH ABDBE ABFSG ABIVO ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMFV ACMJI ACPRK ACRQY ACSTC ACZOJ ADBBV ADFRT AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG ATHPR AVWKF AYFIA AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 DIK DNIVK DPUIP DWQXO E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FDB FDQFY FERAY FIZPM FSGXE FYUFA GNUQQ GX1 HCIFZ HMCUK HYE HZ~ IWAJR JSO JZLTJ KQ8 M1P M2M M7P MK0 NQJWS O9- OK1 P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO PSYQQ Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI --K 1B1 53G 5VS AACDK AAEDT AALRI AAQFI AAQXK AATNV AAXUO ABMAC ABWVN ACIUM ACRPL ADMUD ADNMO CAG CGR COF CUY CVF ECM EIF FEDTE FGOYB FIGPU HVGLF IHE LGEZI LOTEE M41 NADUK NPM NQ- NXXTH R2- RIG RNS RPZ SEW SSZ ZKB 3V. 7TK 7XB 8FE 8FH 8FK ABRTQ K9. LK8 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c478t-3eac5218cff15baeb26b70f17dec175fb18d51bc969ad2a60d0706bc6351354b3 |
IEDL.DBID | BENPR |
ISSN | 0893-133X 1740-634X |
IngestDate | Thu Aug 21 18:33:02 EDT 2025 Fri Sep 05 09:08:42 EDT 2025 Fri Sep 05 04:25:16 EDT 2025 Fri Jul 25 09:02:19 EDT 2025 Thu Apr 03 07:09:10 EDT 2025 Tue Jul 01 01:05:28 EDT 2025 Thu Apr 24 22:58:03 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c478t-3eac5218cff15baeb26b70f17dec175fb18d51bc969ad2a60d0706bc6351354b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://www.nature.com/articles/npp2014193.pdf |
PMID | 25074639 |
PQID | 1635037817 |
PQPubID | 33935 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4443960 proquest_miscellaneous_1664208374 proquest_miscellaneous_1637552864 proquest_journals_1635037817 pubmed_primary_25074639 crossref_citationtrail_10_1038_npp_2014_193 crossref_primary_10_1038_npp_2014_193 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-01-01 |
PublicationDateYYYYMMDD | 2015-01-01 |
PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: New York |
PublicationTitle | Neuropsychopharmacology (New York, N.Y.) |
PublicationTitleAlternate | Neuropsychopharmacology |
PublicationYear | 2015 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | J Chen (BFnpp2014193_CR5) 2004; 75 TV Maia (BFnpp2014193_CR18) 2011; 14 AS Kayser (BFnpp2014193_CR16) 2012; 32 N Ramnani (BFnpp2014193_CR22) 2004; 5 JB Rotter (BFnpp2014193_CR23) 1966; 80 JA Gogos (BFnpp2014193_CR14) 1998; 95 MJ Frank (BFnpp2014193_CR13) 2011; 36 JM Mitchell (BFnpp2014193_CR19) 2005; 29 CD Spielberger (BFnpp2014193_CR25) 1983 DY Kimberg (BFnpp2014193_CR17) 1997; 8 R Cools (BFnpp2014193_CR7) 2011; 69 JH Patton (BFnpp2014193_CR21) 1995; 51 MJ Frank (BFnpp2014193_CR12) 2009; 12 D Badre (BFnpp2014193_CR2) 2012; 73 R Ceravolo (BFnpp2014193_CR4) 2002; 43 B De Brabander (BFnpp2014193_CR9) 2004; 37 C Stelzel (BFnpp2014193_CR26) 2009; 29 CH Declerck (BFnpp2014193_CR10) 2006; 62 AG Collins (BFnpp2014193_CR6) 2014; 121 JA Apud (BFnpp2014193_CR1) 2007; 32 I Dumontheil (BFnpp2014193_CR11) 2008; 50 CT Smith (BFnpp2014193_CR24) 2012; 222 GP Strauss (BFnpp2014193_CR27) 2011; 69 ND Daw (BFnpp2014193_CR8) 2006; 441 K Kalidindi (BFnpp2014193_CR15) 2007; 20 J Vytlacil (BFnpp2014193_CR28) 2014; 9 JF Cavanagh (BFnpp2014193_CR3) 2012; 22 AA Moustafa (BFnpp2014193_CR20) 2008; 28 17063156 - Neuropsychopharmacology. 2007 May;32(5):1011-20 9707588 - Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9991-6 11793426 - Synapse. 2002 Mar 1;43(3):201-7 20631684 - Neuropsychopharmacology. 2011 Jan;36(1):133-52 16778890 - Nature. 2006 Jun 15;441(7095):876-9 9427330 - Neuroreport. 1997 Nov 10;8(16):3581-5 16806623 - Brain Cogn. 2006 Nov;62(2):143-76 19020023 - J Neurosci. 2008 Nov 19;28(47):12294-304 16385186 - Alcohol Clin Exp Res. 2005 Dec;29(12):2158-69 22349272 - Psychopharmacology (Berl). 2012 Aug;222(4):609-17 19291230 - Eur J Neurosci. 2009 Mar;29(5):1056-63 5340840 - Psychol Monogr. 1966;80(1):1-28 17574813 - Neural Netw. 2007 Aug;20(6):676-89 21168124 - Biol Psychiatry. 2011 Mar 1;69(5):424-31 14976518 - Nat Rev Neurosci. 2004 Mar;5(3):184-94 22120491 - Cereb Cortex. 2012 Nov;22(11):2575-86 8778124 - J Clin Psychol. 1995 Nov;51(6):768-74 21531388 - Biol Psychiatry. 2011 Jun 15;69(12):e113-25 24498023 - PLoS One. 2014;9(1):e87109 15457404 - Am J Hum Genet. 2004 Nov;75(5):807-21 19620978 - Nat Neurosci. 2009 Aug;12(8):1062-8 22325209 - Neuron. 2012 Feb 9;73(3):595-607 21270784 - Nat Neurosci. 2011 Feb;14(2):154-62 25090423 - Psychol Rev. 2014 Jul;121(3):337-66 22764248 - J Neurosci. 2012 Jul 4;32(27):9402-9 18190537 - Dev Med Child Neurol. 2008 Mar;50(3):168-81 |
References_xml | – volume: 32 start-page: 1011 year: 2007 ident: BFnpp2014193_CR1 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301227 – volume: 73 start-page: 595 year: 2012 ident: BFnpp2014193_CR2 publication-title: Neuron doi: 10.1016/j.neuron.2011.12.025 – volume: 20 start-page: 676 year: 2007 ident: BFnpp2014193_CR15 publication-title: Neural Netw doi: 10.1016/j.neunet.2007.04.026 – volume: 69 start-page: e113 year: 2011 ident: BFnpp2014193_CR7 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2011.03.028 – volume: 37 start-page: 735 year: 2004 ident: BFnpp2014193_CR9 publication-title: Personality and Individual Differences doi: 10.1016/j.paid.2003.11.001 – volume-title: Manual for the state-trait anxiety inventory year: 1983 ident: BFnpp2014193_CR25 – volume: 32 start-page: 9402 year: 2012 ident: BFnpp2014193_CR16 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1180-12.2012 – volume: 95 start-page: 9991 year: 1998 ident: BFnpp2014193_CR14 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.17.9991 – volume: 62 start-page: 143 year: 2006 ident: BFnpp2014193_CR10 publication-title: Brain Cogn doi: 10.1016/j.bandc.2006.04.004 – volume: 441 start-page: 876 year: 2006 ident: BFnpp2014193_CR8 publication-title: Nature doi: 10.1038/nature04766 – volume: 14 start-page: 154 year: 2011 ident: BFnpp2014193_CR18 publication-title: Nat Neurosci doi: 10.1038/nn.2723 – volume: 29 start-page: 1056 year: 2009 ident: BFnpp2014193_CR26 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.2009.06647.x – volume: 9 start-page: e87109 year: 2014 ident: BFnpp2014193_CR28 publication-title: PLoS One doi: 10.1371/journal.pone.0087109 – volume: 29 start-page: 2158 year: 2005 ident: BFnpp2014193_CR19 publication-title: Alcohol Clin Exp Res doi: 10.1097/01.alc.0000191755.63639.4a – volume: 8 start-page: 3581 year: 1997 ident: BFnpp2014193_CR17 publication-title: Neuroreport doi: 10.1097/00001756-199711100-00032 – volume: 121 start-page: 337 year: 2014 ident: BFnpp2014193_CR6 publication-title: Psychol Rev doi: 10.1037/a0037015 – volume: 222 start-page: 609 year: 2012 ident: BFnpp2014193_CR24 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-012-2653-9 – volume: 22 start-page: 2575 year: 2012 ident: BFnpp2014193_CR3 publication-title: Cereb Cortex doi: 10.1093/cercor/bhr332 – volume: 69 start-page: 424 year: 2011 ident: BFnpp2014193_CR27 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2010.10.015 – volume: 28 start-page: 12294 year: 2008 ident: BFnpp2014193_CR20 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3116-08.2008 – volume: 36 start-page: 133 year: 2011 ident: BFnpp2014193_CR13 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2010.96 – volume: 43 start-page: 201 year: 2002 ident: BFnpp2014193_CR4 publication-title: Synapse doi: 10.1002/syn.10034 – volume: 80 start-page: 1 year: 1966 ident: BFnpp2014193_CR23 publication-title: Psychol Monogr doi: 10.1037/h0092976 – volume: 75 start-page: 807 year: 2004 ident: BFnpp2014193_CR5 publication-title: Am J Hum Genet doi: 10.1086/425589 – volume: 12 start-page: 1062 year: 2009 ident: BFnpp2014193_CR12 publication-title: Nat Neurosci doi: 10.1038/nn.2342 – volume: 51 start-page: 768 year: 1995 ident: BFnpp2014193_CR21 publication-title: J Clin Psychol doi: 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1 – volume: 50 start-page: 168 year: 2008 ident: BFnpp2014193_CR11 publication-title: Dev Med Child Neurol doi: 10.1111/j.1469-8749.2008.02026.x – volume: 5 start-page: 184 year: 2004 ident: BFnpp2014193_CR22 publication-title: Nat Rev Neurosci doi: 10.1038/nrn1343 – reference: 20631684 - Neuropsychopharmacology. 2011 Jan;36(1):133-52 – reference: 5340840 - Psychol Monogr. 1966;80(1):1-28 – reference: 21270784 - Nat Neurosci. 2011 Feb;14(2):154-62 – reference: 19291230 - Eur J Neurosci. 2009 Mar;29(5):1056-63 – reference: 9707588 - Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9991-6 – reference: 16806623 - Brain Cogn. 2006 Nov;62(2):143-76 – reference: 22764248 - J Neurosci. 2012 Jul 4;32(27):9402-9 – reference: 24498023 - PLoS One. 2014;9(1):e87109 – reference: 21531388 - Biol Psychiatry. 2011 Jun 15;69(12):e113-25 – reference: 16778890 - Nature. 2006 Jun 15;441(7095):876-9 – reference: 17063156 - Neuropsychopharmacology. 2007 May;32(5):1011-20 – reference: 14976518 - Nat Rev Neurosci. 2004 Mar;5(3):184-94 – reference: 9427330 - Neuroreport. 1997 Nov 10;8(16):3581-5 – reference: 11793426 - Synapse. 2002 Mar 1;43(3):201-7 – reference: 21168124 - Biol Psychiatry. 2011 Mar 1;69(5):424-31 – reference: 15457404 - Am J Hum Genet. 2004 Nov;75(5):807-21 – reference: 22349272 - Psychopharmacology (Berl). 2012 Aug;222(4):609-17 – reference: 18190537 - Dev Med Child Neurol. 2008 Mar;50(3):168-81 – reference: 16385186 - Alcohol Clin Exp Res. 2005 Dec;29(12):2158-69 – reference: 17574813 - Neural Netw. 2007 Aug;20(6):676-89 – reference: 22325209 - Neuron. 2012 Feb 9;73(3):595-607 – reference: 19620978 - Nat Neurosci. 2009 Aug;12(8):1062-8 – reference: 22120491 - Cereb Cortex. 2012 Nov;22(11):2575-86 – reference: 19020023 - J Neurosci. 2008 Nov 19;28(47):12294-304 – reference: 8778124 - J Clin Psychol. 1995 Nov;51(6):768-74 – reference: 25090423 - Psychol Rev. 2014 Jul;121(3):337-66 |
SSID | ssj0015768 |
Score | 2.3900466 |
Snippet | Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision.... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 454 |
SubjectTerms | Adult Behavior Benzophenones - pharmacology Catechol O-Methyltransferase - genetics Catechol O-Methyltransferase - metabolism Catechol O-Methyltransferase Inhibitors - pharmacology Dopamine Dopamine - metabolism Double-Blind Method Exploitation Exploratory Behavior - drug effects Exploratory Behavior - physiology Female Genotype & phenotype Genotyping Techniques Humans Hypotheses Internal-External Control Male Middle Aged Neurology Neuropsychological Tests Nitrophenols - pharmacology Original Polymorphism Reward Uncertainty Young Adult |
Title | Dopamine, Locus of Control, and the Exploration-Exploitation Tradeoff |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25074639 https://www.proquest.com/docview/1635037817 https://www.proquest.com/docview/1637552864 https://www.proquest.com/docview/1664208374 https://pubmed.ncbi.nlm.nih.gov/PMC4443960 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB4VkKpeqrL0sS1FrtRy6aYksWM7pwroIlQVhCqQ9hbFL1GpJAu7e9h_37HjDS-VWySPIyczHn_z8AzA58JRzrLcJjJ3aKBwUyaldizRpbNlrVLrlL_gfHLKjy_Yz0kxiQ63WUyrXOnEoKhNq72PfA9xQ5FSITPxfXqd-K5RProaW2iswQaqYIlyvnEwPj373ccRPJoOOLKkCVpjk5j6nlK510x9ucqMfQtB57uH0iOk-TBh8s4JdPQKXkboSPY7Xm_CM9sMYGu_QbP5akl2SUjmDF7yATw_iTHzAeyeddWplyNyfnvZajYKM_q61cstGP9AA_oK54zIr1YvZqR15LDLZB-RujEEsSLpcvYCO5PwHGt8Ezz0jG2dew0XR-Pzw-MkdllINBNynlBUvXiGS-1cVqgaLW2uROoyYaxGbOFUJk2RKV3ysjZ5zVODWoIrjfzIaMEUfQPrTdvYd0AQDVima1QJwjCX1aXTjNvc4duQFVYN4evqN1c6Ls93wvhbhVA4lRUypfJMqZApQ_jSU0-70hv_odtecayKG3BW3YrLED71w7h1fDykbmy7CDSiKHLJ2VM03CcgUIE0bzsh6BeD6FEwRHhDEPfEoyfwpbvvjzR_LkMJb8YQCPL0_dNL_wAv8COLzuOzDevzm4X9iBhornZgTUzEThT3f7unCVY |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEHR8FAYYie2FhiWxYycPCI2tU8faakKd1LcsdmyBxJJCW6H-U_yNnJ2PbSD2trdIPieO7-z7ne_DAG8jQzkLQu3FoUEDheeJlyjDPJUYnWTS10baBOfxhA_P2OdZNNuA300ujA2rbPZEt1HnpbJn5HuIGyKfijgQH-c_PHtrlPWuNldoVGJxote_0GRbfDg-RP7uhOHRYHow9OpbBTzFRLz0KG41qLNiZUwQyQwtSy6FbwKRa4W61MggzqNAqoQnWR5m3M9xVXCp8PsBjZik-N47sMlsRmsHNj8NJqdfWr-FRe8OtybUQ-tvVofa-zTeK-a2PGbA3jsn91Ul-A-y_TtA84rGO3oID2qoSvYr2XoEG7rowtZ-gWb6xZrsEhc86k7lu3B3XPvou7B7WlXDXvfJ9DK5a9F3Pdo62estGByiwX6BffpkVKrVgpSGHFSR832SFTlBbEqqGEEnPp57rmuKE1SyuS6NeQxntzL_T6BTlIV-BgTRh2Yqwy1I5MwEWWIU4zo0-DZkhZY9eNdMc6rq4dmbN76nzvVO4xSZklqmpMiUHuy01POq1Md_6LYbjqX1gl-kl-LZgzdtMy5V63_JCl2uHI2IojDm7CYabgMeqECap5UQtINBtCoYIsoeiGvi0RLYUuHXW4pvX13JcMYQeHL_-c1Dfw33htPxKB0dT05ewH384ag6bdqGzvLnSr9E_LWUr2qhJ3B-2-vsD3saRh4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTpp4QdDxURhgJLYXGhonjp08IDTWVhvbqgptUt-y2LEFEksKbYX6r_HXcXY-toHY294i-Ww5vjvf73znM8DbyISc0UB7cWDQQeF54iXKME8lRieZ9LWR9oLz6YQfnrPPs2i2Ab-buzA2rbLZE91GnZfKnpEPEDdEfihiKgamTouYDscf5z88-4KUjbQ2z2lUInKs17_QfVt8OBoir3eDYDw6Ozj06hcGPMVEvPRC3HbQfsXKGBrJDL1MLoVvqMi1QrtqJI3ziEqV8CTLg4z7OWoIlwrnQsOIyRDHvQebAq0i68Dmp9Fk-qWNYVgk7zBsEnroCc7qtHs_jAfF3JbKpOy9C3hfN4j_oNy_kzWvWb_xQ3hQw1ayX8nZI9jQRRe29wt02S_XZI-4RFJ3Qt-FrdM6Xt-FvWlVGXvdJ2dXF70WfdejrZm93obREJ33S-zTJyelWi1IachBlUXfJ1mRE8SppMoXdKLkue-6vjhBg5vr0pjHcH4n6_8EOkVZ6GdAEIlopjLcjkTODM0SoxjXgcHRkBVa9uBds8ypqqdnX-H4nrowfBinyJTUMiVFpvRgt6WeV2U__kO303AsrZV_kV6Jag_etM2otjYWkxW6XDkaEUVBzNltNNwmP4QCaZ5WQtBOBpGrYIgueyBuiEdLYMuG32wpvn115cMZQxDK_ee3T_01bKF-pSdHk-MXcB__N6oOnnags_y50i8Rii3lq1rmCVzctZr9AVvSSko |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dopamine%2C+Locus+of+Control%2C+and+the+Exploration-Exploitation+Tradeoff&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Kayser%2C+Andrew+S&rft.au=Mitchell%2C+Jennifer+M&rft.au=Weinstein%2C+Dawn&rft.au=Frank%2C+Michael+J&rft.date=2015-01-01&rft.pub=Nature+Publishing+Group&rft.issn=0893-133X&rft.eissn=1740-634X&rft.volume=40&rft.issue=2&rft.spage=454&rft_id=info:doi/10.1038%2Fnpp.2014.193&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3522567981 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon |